TABLE 1

Clinical and metabolic characteristics of PCOS patients and control subjects

Control subjectsPCOS patientsPCOS pretreatmentPCOS posttreatment
n14241010
Age (years)33.8 ± 2.131.6 ± 1.330.3 ± 2.1
Weight (kg)98.2 ± 3.896.2 ± 2.296.4 ± 2.595.5 ± 2.8
BMI (kg/m2)33.7 ± 1.733.3 ± 0.933.2 ± 0.933.0 ± 1.1
Body fat (%)40.5 ± 1.640.3 ± 1.139.1 ± 1.339.8 ± 1.4
Plasma triglycerides (mmol/l)0.86 ± 0.111.66 ± 0.18*1.43 ± 0.221.15 ± 0.16
Serum free testosterone (mg/l)0.025 ± 0.0030.048 ± 0.005*0.053 ± 0.0090.048 ± 0.007
Plasma glucose (mmol/l)5.6 ± 0.15.9 ± 0.15.9 ± 0.25.6 ± 0.1
Serum insulin (pmol/l)51 ± 6104 ± 12**125 ± 2269 ± 11††
Plasma FFA basal (mmol/l)0.47 ± 0.040.44 ± 0.030.45 ± 0.050.41 ± 0.05
Rd basal (mg · min−1 · m−2)72 ± 377 ± 275 ± 376 ± 4
Rd clamp (mg · min−1 · m−2)297 ± 23150 ± 9*138 ± 18188 ± 25
Glucose oxidation basal (mg · min−1 · m−2)52 ± 842 ± 346 ± 543 ± 10
Glucose oxidation clamp (mg · min−1 · m−2)141 ± 1786 ± 5*80 ± 10101 ± 12††
Lipid oxidation basal (mg · min−1 · m−2)33 ± 339 ± 138 ± 140 ± 4
Lipid oxidation clamp (mg · min−1 · m−2)1 ± 623 ± 2*24 ± 416 ± 5
NOGD basal (mg · min−1 · m−2)20 ± 735 ± 330 ± 534 ± 9
NOGD clamp (mg · min−1 · m−2)157 ± 2265 ± 6*58 ± 1287 ± 14
  • Data are means ± SEM. Differences between control subjects and all PCOS patients before randomization to TZD as well as the effect of 16 weeks of treatment with 30 mg pioglitazone once daily in 10 PCOS patients were tested using one-way or two-way ANOVA for repeated measures. The 38 study subjects represent a subcohort of a total of 44 subjects for which data have been presented previously (2).

  • *

    * P < 0.001 and

  • **

    ** P < 0.01 vs. PCOS patients;

  • P < 0.01 and

  • ††

    †† P < 0.05 vs. pretreatment.